Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shawn Flanagan

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The Journal of Antimicrobial Chemotherapy|November 14, 2024
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometricsDavid Andes, Roger J Brüggemann, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|October 22, 2014
Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionShawn Flanagan, Edward E McKee, Debaditya Das, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 31, 2026
Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenzaJan Snoeys, Grayson Hough, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2025
Activity of rezafungin against Candida aurisJeffrey B Locke, David Andes, Shawn Flanagan, et al.
Clinical Pharmacokinetics|December 15, 2010
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingMark Fineman, Shawn Flanagan, Kristin Taylor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2025
Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a StudyRoxana E Rojas, Ozlem Equils, Jorge Villacian, et al.
Nature Microbiology|March 18, 2025
Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in miceSimon Döhrmann, James Levin, Jason N Cole, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The Journal of Antimicrobial Chemotherapy|November 14, 2024
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometricsDavid Andes, Roger J Brüggemann, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|October 22, 2014
Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionShawn Flanagan, Edward E McKee, Debaditya Das, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 31, 2026
Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenzaJan Snoeys, Grayson Hough, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2025
Activity of rezafungin against Candida aurisJeffrey B Locke, David Andes, Shawn Flanagan, et al.
Clinical Pharmacokinetics|December 15, 2010
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingMark Fineman, Shawn Flanagan, Kristin Taylor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2025
Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a StudyRoxana E Rojas, Ozlem Equils, Jorge Villacian, et al.
Nature Microbiology|March 18, 2025
Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in miceSimon Döhrmann, James Levin, Jason N Cole, et al.
Pageof 3